The WACC of ImmuPharma PLC (IMM.L) is 9.5%.
| Range | Selected | |
| Cost of equity | 11.80% - 17.40% | 14.60% |
| Tax rate | 9.80% - 12.20% | 11.00% |
| Cost of debt | 5.00% - 5.00% | 5.00% |
| WACC | 8.1% - 10.9% | 9.5% |
| Category | Low | High |
| Long-term bond rate | 4.0% | 4.5% |
| Equity market risk premium | 6.0% | 7.0% |
| Adjusted beta | 1.3 | 1.78 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 11.80% | 17.40% |
| Tax rate | 9.80% | 12.20% |
| Debt/Equity ratio | 1 | 1 |
| Cost of debt | 5.00% | 5.00% |
| After-tax WACC | 8.1% | 10.9% |
| Selected WACC | 9.5% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for IMM.L:
cost_of_equity (14.60%) = risk_free_rate (4.25%) + equity_risk_premium (6.50%) * adjusted_beta (1.3) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.